Back to news

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire•17/11/2026•16:01 ET
0

Key Highlights

  • ➤Stoke granted options for 99,050 shares to eleven new employees.
  • ➤Options carry a $26.63 exercise price, matching Stoke’s November 16 closing price.
  • ➤Options vest over four years and expire after 10 years.
  • ➤Zorevunersen is being evaluated in a Phase 3 Dravet syndrome study.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on November 16, 2026, it granted stock options to purchase an aggregate of 99,050 shares of common stock to eleven new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in